Cervical cancer
A Study Testing a New Treatment Plan Combining Chemo and Immunotherapy for Women with High Risk Advanced Cervical Cancer
Who can joinWomen
Age18–70 years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine and radiation
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
All India Insitute of Medical Sciences new DelhiNew Delhi, DelhiDirections ↗
Registry summary (technical)
Neo-adjuvant chemo-immunotherapy followed by chemoradiation and maintenance immunotherapy for high-risk locally advanced cervical cancer (LACC): A phase 3, randomised, open-label, multicentre study
Sponsor: Indian council of Medical research
CTRI/2026/06/112930 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 14 Sep 2026 · read by us 5 Nov 2026